Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methysergide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 1.00 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 1.00 |
| ▸ | HTR2B known ✓ | P41595 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 10/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 1.00 |
| ▸ | MEN1 | O00255 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 8/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 1.00 |
| ▸ | HPGD | P15428 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | GLA | P06280 | 2/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 2/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | HRH2 | P25021 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methysergide SCHEMBL29359107 | 1.00 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4ECYP2D6 | |
| Methysergide SCHEMBL467884 | 1.00 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4ECYP2D6 | |
| Methysergide SCHEMBL467883 | 1.00 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4ECYP2D6 | |
| Methysergide SCHEMBL7088235 | 0.99 | KMT2A (0.98) | KMT2AALDH1A1MEN1KDM4ECYP2D6 | |
| Methysergide SCHEMBL28086572 | 0.99 | KMT2A (0.98) | KMT2AALDH1A1MEN1KDM4ECYP2D6 | |
| Methsergide SCHEMBL29601488 | 0.95 | KMT2A (0.91) | KMT2AALDH1A1MEN1KDM4ECYP2D6 | |
| Methysergide SCHEMBL41844 | 0.95 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4ECYP2D6 | |
| Methysergide SCHEMBL21803661 | 0.95 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4ECYP2D6 | |
| Methysergide SCHEMBL29408580 | 0.95 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4ECYP2D6 | |
| Methysergide SCHEMBL28196309 | 0.95 | KMT2A (1.00) | KMT2AALDH1A1MEN1KDM4ECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8946 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725483-A1 | COMBINATION COMPRISING AT LEAST ONE 5-HT2A RECEPTOR ANTAGONIST AND AT LEAST ONE 5-HT3 RECEPTOR ANTAGONIST AND ITS MEDICAL USE | Université de Bordeaux (FR) | 2026-04-15 | — | — | EP | claimed |
| EP-4674894-A2 | COPOLYMERS OF N-VINYLPYRROLIDONE WITH FUNCTIONALIZED MALEIC ACID MOIETIES | Hemoteq AG (DE) | 2026-01-07 | — | — | EP | claimed |
| US-20250381175-A1 | COMPOUNDS FOR INCREASING NEURAL PLASTICITY | UNIV CALIFORNIA (US) | 2025-12-18 | — | — | US | claimed |
| EP-4663688-A2 | CROSSLINKERS | Hemoteq AG (DE) | 2025-12-17 | — | — | EP | claimed |
| US-20250295611-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS INC (US) | 2025-09-25 | — | — | US | claimed |
| US-20250255755-A1 | WOUND HEALING DEVICE AND METHODS FOR WOUND HEALING | SINUS CLEAR INNOVATIONS LLC (US) | 2025-08-14 | — | — | US | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20250169715-A1 | USE OF BLINK REFLEX FOR HEADACHE RESPONSE MONITORING AND/OR TREATMENT SELECTION | BLINKTBI INC (US) | 2025-05-29 | — | — | US | claimed |
| EP-4558219-A1 | NEUTRALIZATION OF ACYL-COA BINDING PROTEIN FOR THE TREATMENT OF CARDIAC DYSFUNCTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2025-05-28 | — | — | EP | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| WO-1990004387-A2 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-05-03 | — | — | WO | claimed |
| EP-0335966-A4 | VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS. | MATRIX PHARMA INC (US) | 1990-02-20 | — | — | EP | claimed |
| EP-0335966-A1 | VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS | MATRIX PHARMACEUTICALS, INC. (US) | 1989-10-11 | — | — | EP | claimed |
| WO-1989003692-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-05-05 | — | — | WO | claimed |
| WO-1989002734-A1 | VASOCONSTRICTIVE SUBSTANCES IN COMBINATION WITH CYTOTOXIC AGENTS | MATRIX PHARMACEUTICALS, INC. (US) | 1989-04-06 | — | — | WO | claimed |
| US-4704394-A | SEROTONIN ANTAGONISTS | TECHNOLOGY UNLIMITED, INC. (US) | 1987-11-03 | — | — | US | claimed |
| EP-0155229-A2 | Pharmaceutical compositions | SANDOZ AG (CH) | 1985-09-18 | — | — | EP | claimed |
| WO-1985003878-A1 | PHARMACEUTICAL COMPOSITIONS | SANDOZ AG (CH) | 1985-09-12 | — | — | WO | claimed |
| EP-0152379-A2 | Process for preparing pharmaceutical compositions containing unilamellar liposomes | CIBA-GEIGY AG (CH) | 1985-08-21 | — | — | EP | claimed |
| US-4444778-A | ANTISEROTONINE AGENTS | COUGHLIN SHAUN R | 1984-04-24 | — | — | US | claimed |